ICER’s Final Evidence Report on bluebird bio’s Gene Therapy, beti-cel, Highlights Alternative Payment Model for One-Time Curative Treatment
In July, the Institute for Clinical and Economic Review (ICER) published its final evidence report for bluebird bio’s Zynteglo (betibeglogene autotemcel or “beti-cel”) for the treatment of beta thalassemia, a rare, debilitating blood disorder.